Homepage Top Section2

The merger of Bristol-Myers Squibb and Celgene is expected to result in a specialty biopharma company that will strive to develop high-value innovative medicines to meet the needs

ITOCHU is the first lead investor in Promethera’s new investment round, which is expected to be completed in the first quarter of this year. The US pharma firm is

Antengene has secured the money under series B financing round led by Boyu Capital and FountainVest. The participants include new investors such as Celgene, WuXi Corporate Venture Fund

The vaccine, called Vaxelis, is indicated to prevent diphtheria, tetanus, poliomyelitis, pertussis, hepatitis B and invasive disease due to Haemophilus influenzae type b. It has been approved for

ACO is commonly associated with the ingestion of ‘edibles’ such as brownies, cookies and candies that contain large quantities of  D9-tetrahydrocannabinol (THC) and synthetic cannabinoids that are more

PCOS is the most common endocrine disorder found in reproductive-age women, and is a major cause of infertility and type 2 diabetes. The source of the disease is

PNH is a rare and acquired blood disease that results in the rupture or destruction of red blood cells (hemolysis). People diagnosed with PNH lack a certain protein

According to Pfizer, the combination of the consumer healthcare businesses had registered global sales of nearly $12.7bn in 2017. GSK said that the combination will comprise two portfolios

Roxadustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) indicated to treat patients who use hemodialysis or peritoneal dialysis. It will help induce coordinated erythropoiesis, increase red blood